The Effect of Escitalopram on Exacerbation Rates and Quality of Life in Patients With Anxiety Associated With Severe COPD
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Escitalopram (Primary)
- Indications Anxiety
- Focus Therapeutic Use
- 19 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 22 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 22 Mar 2015 Planned initiation date changed from 1 Feb 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.